Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the
growth of myelodysplastic cells, either by killing the cells or by stopping them from
dividing. Tretinoin and decitabine may help myelodysplastic cells become more like normal
cells, and to grow and spread more slowly. Giving decitabine together with tretinoin may be
an effective treatment for myelodysplastic syndromes.
PURPOSE: This phase I/II trial is studying the side effects and best dose of tretinoin when
given together with decitabine in treating patients with myelodysplastic syndromes.